Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma

被引:6
|
作者
Esteban, Jesus Rivera- [1 ,2 ,3 ]
Munoz-Martinez, Sergio [2 ,4 ]
Higuera, Monica [2 ]
Sena, Elena [2 ]
Bermudez-Ramos, Maria [2 ,5 ]
Banares, Juan [2 ]
Martinez-Gomez, Maria [2 ]
Cusido, M. Serra [2 ]
Jimenez-Masip, Alba
Francque, Sven M. [6 ,7 ]
Tacke, Frank [8 ]
Minguez, Beatriz [2 ,3 ,9 ]
Pericas, Juan M. [2 ,3 ,9 ]
机构
[1] Vall Dhebron Univ Hosp, Dept Internal Med, Liver Unit, Barcelona, Spain
[2] Vall dHebron Barcelona Campus Hosp, Vall dHebron Inst Recerca VHIR, Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Hosp Univ Germans Trias i Pujol, Dept Digest Dis, Liver Unit, Badalona, Spain
[6] Antwerp Univ Hosp, Dept Gastroenterol Hepatol, Edegem, Belgium
[7] Univ Antwerp, Fac Med & Hlth Sci, InflaMed Ctr Excellence, Lab Expt Med & Paediat Translat Sci Inflammat & Im, Antwerp, Belgium
[8] Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Campus Virchow Klinikum & Campus Charite Mitte, Berlin, Germany
[9] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
基金
欧盟地平线“2020”;
关键词
Hepatocellular Carcinoma; Metabolic Dysfunction-Associated - Associated Steatotic Liver Disease; MASLD; NAFLD; Phenotypes; ATEZOLIZUMAB PLUS BEVACIZUMAB; NONALCOHOLIC STEATOHEPATITIS; DIABETES-MELLITUS; INCREASED RISK; CONFERS SUSCEPTIBILITY; COST-EFFECTIVENESS; MURINE MODEL; LIFE-STYLE; OPEN-LABEL; CANCER;
D O I
10.1016/j.cgh.2024.03.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) typically develops as a consequence of liver cirrhosis, but HCC epidemiology has evolved drastically in recent years. Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis, has emerged as the most common chronic liver disease worldwide and a leading cause of HCC. A substantial proportion of MASLD-associated HCC (MASLD-HCC) also can develop in patients without cirrhosis. The specific pathways that trigger carcinogenesis in this context are not elucidated completely, and recommendations for HCC surveillance in MASLD patients are challenging. In the era of precision medicine, it is critical to understand the processes that define the profiles of patients at increased risk of HCC in the MASLD setting, including cardiometabolic risk factors and the molecular targets that could be tackled effectively. Ideally, defining categories that encompass key pathophysiological features, associated with tailored diagnostic and treatment strategies, should facilitate the identification of specific MASLD-HCC phenotypes. In this review, we discuss MASLD-HCC, including its epidemiology and health care burden, the mechanistic data promoting MASLD, metabolic dysfunction-associated steatohepatitis, and MASLD-HCC. Its natural history, prognosis, and treatment are addressed specifically, as the role of metabolic phenotypes of MASLD-HCC as a potential strategy for risk stratification. The challenges in identifying high-risk patients and screening strategies also are discussed, as well as the potential approaches for MASLD-HCC prevention and treatment.
引用
收藏
页数:24
相关论文
共 50 条
  • [31] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [32] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [33] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [34] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [35] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [36] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [37] Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease
    Savytska, Maryana
    Baka, Olena
    Manzhalii, Elina
    Kyriienko, Dmytro
    Falalyeyeva, Tetyana
    Zhayvoronok, Maksym
    Kovalchuk, Oleksandr
    Deresh, Nataliya
    Grygoriev, Fedir
    Kobyliak, Nazarii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S611
  • [38] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [39] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [40] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552